A US Stock PLTR, Market structure update and strategy👋Hello Traders,
Our 🖥️ AI system detected that there is an D1 timeframe ICT Short setup in PLTR for Swing trade.
Technically it is clearly that a double top formation and a LG at second top.
Our idea:
if Closed below 71.0, it will find the next support level 63.6 above the demand zone.
There will be a good chance to buy after next accumulation next time.
Since we have stock on hand,
we will use Option strategy such as Short Call about 77 to collect premium.
For more ideas, you are welcome to visit our profile in tradingview.
Have a good day!
Please give this post a like if you like this kind of simple idea, your feedback will bring our signal to next better level, thanks for support!
Usstocks
Atour: The Smart Way to Invest in China's Hospitality Market◉ Abstract
Atour Lifestyle Holdings Limited is taking advantage of China's fast-growing hotel industry. The hospitality sector of China is expected to reach $157.46 billion by 2032, growing at a rate of 8.23% each year. This growth comes from a strong economy, more people moving to cities, and an increase in travel. Atour uses a smart business model that allows for quick expansion while keeping costs low. They offer a variety of hotel brands and even sell sleep-related products.
In FY23, Atour's sales jumped to $657.4 million, a 106% increase from the previous year, along with strong earnings growth. With over 83 million members in its loyalty program and a focus on great customer experiences, Atour is set for continued success in China's hospitality market.
Overview of the Hotel Service Industry in China.
Continue reading full article here:
◉ Overview of the Hotel Service Industry in China
China's hotel service industry is on the cusp of a remarkable growth spurt, fueled by the country's soaring economy, rapid urbanization, and an unprecedented surge in domestic and foreign travel.
● Projected Market Value: $157.46 billion by 2032
● Growth Rate: 8.23% Compound Annual Growth Rate (CAGR) from 2024 to 2032
◉ What's Driving this Growth?
● Economic Growth: China's economy continues to expand, boosting disposable incomes and travel budgets.
● Urbanization: As more Chinese citizens move to cities, they're seeking better travel experiences and accommodations.
● Increased Travel: Both domestic and foreign travel are on the rise, driving demand for hotels and travel services.
As China's hotel service industry experiences rapid growth, Atour Lifestyle Holdings NASDAQ:ATAT Company has established itself as a prominent force in the market. By delivering a unique blend of comfort, style, and local charm, Atour is redefining the hospitality landscape in China.
Atour's strategic focus on mid-to-upscale hotels enables the company to provide immersive local experiences, innovative design, and exceptional service. This distinctive approach has fostered a loyal customer base and positioned Atour for continued success in China's burgeoning hotel market.
◉ Investment Advice
💡 Buy Atour Lifestyle Holdings NASDAQ:ATAT
● Buy Range - 27 - 27.5
● Sell Target - 36 - 37
● Potential Return - 30% - 35%
● Approx Holding Period - 12-14 months
◉ Business Model
Atour Lifestyle Holdings Limited utilizes an asset-light, franchise-oriented business model that enables rapid expansion and operational efficiency in China's hotel industry. Here are the key components:
● Manachised Model: Atour primarily operates through a "manachised" model, where franchisees handle capital expenditures and hotel leases while Atour provides management and training. This approach minimizes operational costs and maximizes revenue from franchise royalties.
● Diverse Brand Portfolio: The company offers various hotel brands, including Atour, Atour S, Atour X, and ZHOTEL, catering to different market segments and customer preferences.
● Retail Integration: Atour has expanded into retail by selling sleep-related products, generating significant revenue and enhancing the guest experience.
● Customer Loyalty Programs: The A-CARD loyalty program boasts over 63 million members, driving customer retention and engagement through various benefits.
● Digital Capabilities: Atour leverages technology for a seamless customer experience, allowing easy online bookings and efficient communication during stays.
● Focus on Experience: The company emphasizes delivering unique lifestyle experiences through thematic hotels and tailored offerings.
◉ Key Competitors
1. Huazhu Group (H World Group): A leading competitor with over 10,150 hotels, Huazhu operates a similar manachised model and has been expanding rapidly, making it one of the largest players in the market.
2. Jin Jiang International: With a vast portfolio exceeding 12,000 hotels, Jin Jiang is another major competitor that employs a mix of franchising and management strategies.
3. GreenTree Hospitality Group: Focused on midscale accommodations, GreenTree operates around 3,000 hotels and utilizes a franchise-based model with manachised elements.
4. BTG Homeinns Hotels: Known for its budget offerings, BTG Homeinns has a significant presence with thousands of hotels primarily targeting domestic travelers.
5. Plateno Group (7 Days Inn): Operating primarily in the budget segment, Plateno utilizes a manachised approach to grow its network of over 3,000 hotels.
These companies dominate the domestic market, while international brands like InterContinental Hotels Group (IHG) and Shangri-La Hotels & Resorts lead the high-end segment.
◉ Strategic Initiatives Powering Atour's Growth Trajectory
● Expanded Hotel Network: 140 new hotels added in Q3 and 732 under development, increasing capacity and driving revenue growth.
● Upscale Brand Introduction: SAVHE Hotel launch in core business districts, enhancing occupancy and average daily rate (ADR).
● Retail Segment Growth: 107.7% year-over-year GMV growth in 'deep sleep' products, boosting revenue and net margins.
● Membership Base Expansion: Over 83 million members, increasing revenue potential through customer loyalty and repeated business.
◉ Revenue & Profit Analysis
● Year-on-year
➖ FY23 sales reached $657.4 million, a remarkable 106% increase from $328 million in FY22.
➖ EBITDA surged to $142 million, up from $36 million in FY22.
➖ The EBITDA margin widened to 21.6% from 11.15% in the same period.
● Quarter-on-quarter
➖ Q3 sales reached $270 million, a 9% increase from $247 million in Q2 and a 52% jump from $177 million in Q3 2023.
➖ Q3 EBITDA climbed to $72.6 million, up from $56.2 million in Q2.
➖ Q3 diluted EPS rose to $0.39 (LTM) from $0.30 (LTM) in Q2 2024.
◉ Valuation
● P/E Ratio
ATAT has a P/E ratio of 24x, which is fairly valued when compared to the peer average of 23.7x.
● PEG Ratio
With a PEG ratio of just 0.15, ATAT appears to be undervalued based on its anticipated earnings growth.
◉ Profitability Analysis
With a 30.7% ROCE, ATAT demonstrates its expertise in generating substantial profits through efficient capital allocation.
◉ Cash Flow Analysis
ATAT achieves remarkable growth in operational cash flow, rising 582% to $280 million in FY23 from $41 million in FY22.
◉ Debt Analysis
ATAT's debt-to-equity ratio stands at 0.67, signaling that debt is not a significant concern for the company.
◉ Top Shareholders
➖ Mr. Haijun Wang, CEO of Atour Lifestyle Holdings, holds a significant 19.2% stake.
➖ Trip.com Group Limited holds approximately 13.6% stake.
◉ Technical Aspects
➖ The weekly chart indicates that after a long period of consolidation, the stock price has formed a Rounding Bottom Pattern and is likely to break through its strong resistance zone soon.
➖ A Pole & Flag pattern has formed on the daily chart, with the stock price targeting higher levels following a successful breakout.
◉ Conclusion
Following a thorough analysis, we believe Atour presents a lucrative investment opportunity. With its appealing valuation, impressive financial track record, and strategic growth initiatives, Atour is well-positioned to capitalize on the growing tourism sector. The company's commitment to delivering exceptional customer experiences further strengthens its potential for long-term growth and value creation for shareholders.
Tesla's Electrifying Rally: Stock Zooms to New Peaks● After facing a notable setback at the $415 mark, the stock took a dramatic plunge, dropping around 75% before finding its footing close to the $100 threshold.
● Following this, the stock entered an extended period of consolidation, eventually created a Rounding Bottom pattern.
● Recently, the stock has surpassed its previous resistance and reached all-time high.
● This breakthrough has sparked significant excitement, with optimism soaring about the stock's future growth potential.
Investing in Cybersecurity: PANW vs CRWD vs FTNT◉ Abstract
The cybersecurity landscape is rapidly evolving, with emerging threats and innovative solutions driving growth in the industry. This article examines the competitive dynamics between three leading cybersecurity stocks: Palo Alto Networks (PANW), CrowdStrike (CRWD), and Fortinet (FTNT). As these companies sprint to become the top cybersecurity provider, we analyse their strengths, weaknesses, and strategies for success.
◉ Global Cybersecurity Market Overview
The global cybersecurity market has experienced significant growth and is projected to continue expanding in the coming years. As of 2023, the market was valued at approximately USD 192.4 billion and is expected to reach between USD 501 billion and USD 608 billion by 2033, with compound annual growth rates (CAGR) ranging from 9% to 12% depending on the source and forecast period considered.
◉ Growth Drivers
1. Increasing Cyber Threats: The frequency and sophistication of cyber-attacks, including ransomware and data breaches, are rising, prompting organizations to enhance their security measures.
2. Digital Transformation: The rapid adoption of digital technologies, such as cloud computing and the Internet of Things (IoT), expands the attack surface and necessitates robust cybersecurity solutions.
3. Regulatory Compliance: Stricter regulations regarding data protection, like GDPR and CCPA, compel organizations to invest in cybersecurity to ensure compliance and protect sensitive information.
4. Proliferation of Smart Devices: The increasing use of connected devices in homes and industries creates more entry points for cyber threats, driving demand for advanced security solutions.
5. E-commerce Growth: The rise in online transactions increases the need for secure payment systems and data protection, further fuelling the cybersecurity market.
Remote Work Trends: The shift towards remote work has heightened the need for secure remote access solutions to protect organizational data from cyber threats.
◉ Regional Insights
● North America: This region dominates the global cybersecurity market, accounting for over 36% of the market share. The presence of major tech firms and a high incidence of cyber threats contribute to its leadership position.
● Europe: The European market is also growing rapidly due to increased digital transformation efforts and regulatory pressures that emphasize data security.
● Asia-Pacific: Expected to exhibit the fastest growth rate during the forecast period, driven by industrialization, rising internet penetration, and awareness of cybersecurity risks.
◉ Major Players in the Cybersecurity Market
1. Palo Alto Networks NASDAQ:PANW - $132.7 B
2. CrowdStrike Holdings NASDAQ:CRWD - $89.7 B
3. Fortinet NASDAQ:FTNT - $75.26 B
In this comparative analysis we are focused to provide a detailed understanding of the competitive dynamics of three cybersecurity giants: Palo Alto Networks, CrowdStrike Holdings, and Fortinet.
◉ Company Overviews
● Palo Alto Networks
Palo Alto Networks, Inc. is a leading provider of cybersecurity solutions worldwide. The company offers a range of products and services, including network security platforms, cloud security solutions, security operation solutions, subscription services, and professional services. Headquartered in Santa Clara, California, Palo Alto Networks was incorporated in 2005 and has since become a trusted partner for organizations seeking to protect themselves from cyber threats.
● CrowdStrike Holdings
CrowdStrike provides cloud-delivered cybersecurity solutions, offering endpoint, cloud workload, identity, and data protection. Its Falcon platform provides various security services, including threat intelligence, vulnerability management, and AI-powered workflow automation. Headquartered in Austin, Texas, CrowdStrike was incorporated in 2011.
● Fortinet
Fortinet, Inc. was founded in 2000 and is headquartered in Sunnyvale, California. The company provides comprehensive cybersecurity and converged networking and security solutions worldwide. Its offerings include secure networking solutions, network firewall solutions, wireless LAN solutions, and secure connectivity solutions. Additionally, Fortinet provides Unified SASE solutions, security operations solutions, and a range of security services and support. The company serves a diverse customer base, including enterprises, service providers, governments, and small and medium-sized businesses.
◉ Strategic Growth Initiatives of Leading Cybersecurity Players
● Palo Alto Networks
1. Platformization: Transitioning from a traditional firewall vendor to a comprehensive cybersecurity platform provider, offering a wider range of security solutions.
2. Next-Generation Security: Continuing to deliver advanced security solutions to address evolving cyber threats.
● CrowdStrike
1. Innovation: Leveraging AI-powered capabilities to enhance the Falcon platform and maintain a competitive edge in the cybersecurity market.
2. Expansion: Expanding into adjacent markets, such as cloud security and identity protection, to broaden its customer base and product offerings.
● Fortinet
1. "Rule of 45" Framework: Adhering to the "Rule of 45" framework to balance revenue growth with profitability, ensuring a sustainable business model.
2. Product Refresh Cycle: Implementing a strategic product refresh cycle to drive upgrade activity among existing customers and stimulate revenue growth.
◉ Technical Standings
● Palo Alto Networks
➖ The stock has been on a strong upward trajectory, marked by a consistent pattern of higher highs and higher lows.
➖ Following a significant breakout last month, it is currently trading at an all-time high, with expectations for further increases.
● CrowdStrike Holdings
➖ In general, this stock is trending upward, although it has faced considerable price volatility over an extended period.
➖ After reaching an all-time high close to the 400 mark, it underwent a sharp correction.
However, the stock is now climbing again and nearing its previous peak.
● Fortinet
➖ This stock had undergone a lengthy consolidation phase lasting nearly three years, resulting in the development of a Broadening pattern.
➖ After a recent breakout, the price is now targeting new highs.
◉ Relative Strength
➖ The chart clearly demonstrates Fortinet's exceptional performance, showcasing an impressive return of nearly 88%. In comparison, Mastercard and Visa have generated returns of 53% and 41%, respectively.
◉ Revenue & Profit Analysis
● Palo Alto Networks
◾ Year-over-Year
➖ In FY24, Palo Alto Networks (PANW) celebrated an impressive revenue surge of 16.5%, achieving $8,027 million, a notable increase from $6,893 million in FY23.
➖ The EBITDA for FY24 also experienced a substantial boost, reaching $1,094 million, up from $590 million in FY23.
◾ Quarter-over-Quarter
➖ In the most recent October quarter, PANW reported revenues of $2,139 million, a slight dip from the $2,190 million recorded in July 2024. However, this still represents a year-over-year growth of nearly 14% from $1,878 million in the same quarter last year.
➖ The company also reported its highest-ever EBITDA of $413 million in October, an increase from $314 million in July 2024. Compared to the same quarter last year, this figure has risen by almost 20% from $279.5 million.
➖ In October, the diluted EPS rose to $7.69 (LTM), up from $7.28 (LTM) in July 2024, marking an extraordinary year-over-year increase of 333% from $1.78 (LTM).
● CrowdStrike
◾ Year-over-Year
➖ CrowdStrike (CRWD) saw a robust revenue growth of 36.3% in FY23, reaching $3,055 million, up from $2,241 million in FY22.
➖ Conversely, the EBITDA for FY24 has seen a decline, reporting $106 million, down from $118 million in FY23.
◾ Quarter-over-Quarter
➖ In the latest October quarter, CRWD's revenue rose to $1,010 million, compared to $964 million in July 2024. This reflects a year-over-year increase of nearly 28.5% from $786 million in the same quarter last year.
➖ The EBITDA for the most recent June quarter was $15.3 million, showing a significant drop from $52.4 million in July 2024.
➖ In October, the diluted EPS decreased to $0.51 (LTM), down from $0.69 (LTM) in July 2024.
● Fortinet
◾ Year-over-Year
➖ In fiscal year 2023, Fortinet reported a remarkable revenue increase of 20%, reaching $5,304 million, up from $4,417 million in fiscal year 2022.
➖ The EBITDA also saw a significant rise, with the 2023 fiscal year totaling $1,350 million, compared to $1,070 million the previous year.
◾ Quarter-over-Quarter
➖ In the latest September quarter, revenue continued to grow, hitting $1,508 million, an increase from $1,434 million in June 2024. This represents a substantial year-over-year growth of nearly 13% from $1,335 million.
➖ Furthermore, EBITDA for the September quarter neared $500 million, up from $465 million in the prior quarter, reflecting an impressive increase of nearly 51% from $330 million in the same quarter last year.
➖ The diluted earnings per share (EPS) also saw a significant increase in September, rising to $0.7 (LTM) from $0.5 (LTM) in June 2024, marking a notable jump of 70% compared to $0.41 (LTM) in the same quarter last year.
◉ Valuation
● P/E Ratio
➖ PANW stands at a P/E ratio of 48.6x.
➖ CRWD is at a P/E ratio of 707.9x.
➖ FTNT shows a P/E ratio of 49.2x.
◾ These numbers indicate that CRWD is considerably overvalued when compared to its competitors.
● P/B Ratio
➖ PANW's P/B ratio stands at 22.5x.
➖ CRWD's P/B ratio is 29.3x.
➖ On the other hand, FTNT's P/B ratio is significantly higher at 82.9x.
◾ FTNT's high P/B ratio may indicate overvaluation, but its asset-light business model reduces the significance of this metric.
● PEG Ratio
➖ PANW boasts a PEG ratio of 0.14.
➖ CRWD's PEG ratio is recorded at 0.66.
➖ FTNT, meanwhile, has a PEG ratio of 1.26.
◾ Analyzing the PEG ratios reveals that PANW is currently undervalued relative to its peers.
◉ Cash Flow Analysis
➖ PANW has achieved an impressive operating cash flow of $3,257 million for the fiscal year 2024, a substantial rise from $2,777 million in fiscal year 2023.
➖ In a similar vein, CRWD has also seen a positive trend in its operating cash flow, which has climbed to $1,166 million in fiscal year 2024, compared to $941 million the year before.
➖ Furthermore, FTNT has reported a remarkable increase in its operating cash flow, growing from $1,730 million in fiscal year 2022 to $1,935 million in fiscal year 2023.
◉ Debt Analysis
● Palo Alto Networks
➖ Debt to Equity Ratio: Approximately 0.1 as of October 2024, indicating a stable financial structure.
➖ Total Debt: About $645 million.
➖ Total Shareholder Equity: $5,911 million.
◾ PANW's ratio reflects a cautious debt approach, balancing equity and debt financing, with net debt well-supported by operating cash flow, enhancing financial stability.
● CrowdStrike
➖ Debt to Equity Ratio: Approximately 0.24.
➖ Total Debt: $743 million.
➖ Total Shareholder Equity: $3,096 million.
◾ CRWD's ratio suggests a thoughtful strategy regarding debt, maintaining a balance between equity and debt financing.
● Fortinet
➖ Debt to Equity Ratio: Approximately 1.1, indicating a significant level of debt relative to equity.
➖ Total Debt: $993 million.
➖ Total Shareholder Equity: $908 million.
◾ FTNT’s ratio shows a considerable reliance on debt financing, which can facilitate growth but also introduces risks related to interest obligations.
◉ Top Shareholders
● Palo Alto Networks
➖ The Vanguard Group has significantly increased its investment in Palo Alto Networks, now holding an impressive 9.13% stake, which marks a 1.53% rise from the last quarter.
➖ In comparison, Blackrock holds a notable 7.65% share in the company.
● CrowdStrike
➖ Turning to CrowdStrike, The Vanguard Group has also enhanced its position, elevating its ownership to an impressive 8.76%, reflecting a 1.84% increase since the previous quarter.
➖ Conversely, Blackrock possesses a considerable 7.35% stake.
● Fortinet
➖ Regarding Fortinet, The Vanguard Group commands a substantial 8.79% share in the firm.
➖ In contrast, Blackrock holds a 7.44% stake.
◉ Conclusion
After conducting an exhaustive analysis of the major players in the cybersecurity sector, which included an in-depth look at both technical features and financial reports, we have determined that although Palo Alto Networks (PANW) might seem more appealing in terms of valuation, Fortinet (FTNT) stands out as the leading candidate in the industry due to its solid financials. Although concerns about debt exist, the company's strong cash reserves mitigate these worries significantly.
On the other hand, CrowdStrike (CRWD) has faced a recent setback with an outage that has shaken investor trust, leading to a decline in its stock price and rendering it a less favourable investment option for the foreseeable future.
Moreover, the cybersecurity sector is set to grow significantly due to rising cyber threats, fast-paced technology changes, and stricter regulations. Investors are advised to conduct thorough research, define clear investment goals, and maintain a long-term outlook to take advantage of this growth while minimizing risks.
Riding Wave 5: Is $700 Just Around the Corner?Hey Realistic Traders, Will META Bullish Bias Continue ? Let’s Dive In....
In the Daily timeframe, META rebounded above the 38.2% Fibonacci level, marking the completion of wave 4. Within this wave, a Descending broadening wedge pattern was formed. Recently the price has broken out of the pattern. This breakout was further confirmed by a bullish MACD crossover, signaling increasing momentum and strengthening the case for a continued upward move.
Based on these technical signals, I foresee a potential upward movement toward the first target at $638. After reaching this level, a minor pullback is likely before the rally continues toward a new high at $700.
This outlook remains valid as long as the price holds above the stop-loss level at 550.00.
Support the channel by engaging with the content, using the rocket button, and sharing your opinions in the comments below.
Disclaimer: "Please note that this analysis is solely for educational purposes and should not be considered a recommendation to take a long or short position on META.
Amazon Ignites: 150% Blaze Ahead?The stock has been in consolidation since August 2020, forming an Inverted Head & Shoulder pattern. Recently, it broke out above the neckline and is attempting to sustain above the 200 level.
Currently trading at 210, the stock has the potential to surge to 500 levels in the next few years. However, the breakout lacks strong confirmation, as a significant bullish candle with volume expansion is absent.
A crucial factor to watch is a monthly close above 200. This will help determine the stock's future trajectory and guide our trading and investment decisions.
Corcept Therapeutics: A Shining Star in US BiotechCorcept Therapeutics is making waves in the booming U.S. biotech scene, with its stock surging 46.2% over the past six months. The company, known for its Cushing's syndrome drug, Korlym, reported a staggering 39.1% year-over-year sales increase, reaching $310.6 million in H1 2024. With a market cap of $4.42 billion, Corcept is actively developing new treatments like Relacorilant, which shows promise in clinical trials.
Despite a high PE ratio of 35.3x compared to the industry average of 19x, its strong revenue growth and commitment to R&D position it as a solid investment opportunity in the fast-growing biotech market projected to reach $1,786 billion by 2033.
◉ The US Biotech Industry Outlook
The biotech boom in the U.S. is hotter than a California summer! Fueled by groundbreaking tech and government cheerleading, the industry is soaring higher than a SpaceX rocket. According to Vision Research Reports, the market is projected to soar by 12.4% CAGR from 2024 to 2033. This rapid expansion is driven by advancements in areas like genomics, gene editing, and personalized medicine, positioning the U.S. as a global leader in healthcare innovation.
➖ The US biotechnology market size was valued at $552.43 billion in 2023 and is anticipated to hit around $1,786 billion by 2033.
➖ Key players like Abbvie Inc., Genentech Inc., and Amgen Inc. are leading the market.
Acknowledging the remarkable expansion of the biotech sector, we are taking a closer look at a stock that is showing considerable strength in its technical chart, complemented by robust financial performance.
◉ Company Overview
Corcept Therapeutics NASDAQ:CORT is a biopharmaceutical company dedicated to developing innovative treatments for severe endocrine, oncologic, and metabolic disorders. Their lead product, Korlym, is approved for Cushing's syndrome, a rare endocrine condition. Corcept is also advancing several pipeline candidates, including relacorilant for Cushing's syndrome, treatments for various cancers, and potential therapies for neurological conditions like amyotrophic lateral sclerosis and nonalcoholic steatohepatitis. Founded in 1998, Corcept is based in Menlo Park, California.
◉ Significant Stock Performance of Corcept Therapeutics
Corcept Therapeutics Incorporated's stock price has risen 46.2% in the past six months, despite a 2% industry decline. This surge is attributed to strong demand for Korlym, the company's sole marketed drug used to treat Cushing's syndrome, a condition that is primarily cured with mifepristone.
◉ The Economic Impact of Korlym
The primary source of revenue for Corcept emanates from the sales of Korlym. The drug has showcased remarkable growth, evidenced by a 39.1% year-over-year sales increase, culminating in $310.6 million during the first half of 2024. This growth is attributed to robust demand and an unprecedented number of patients being prescribed the medication.
◉ Corcept's Stock Growth Factors
● Potential of Relacorilant: Positive GRACE study results suggest relacorilant could be a valuable treatment for Cushing's syndrome, potentially driving revenue growth.
● Pipeline Diversification: Corcept's ongoing exploration of relacorilant in GRADIENT study demonstrates commitment to expanding pipeline.
● Regulatory Progress: Successful completion of GRACE study positions Corcept for a new drug application in late 2024.
● Market Need: Successful relacorilant could fill significant unmet medical need for Cushing's syndrome.
Investent Advice by Naranj Capital
Buy Corcept Therapeutics NASDAQ:CORT
● Buy Range- 38 - 40
● Target- 55 - 58
● Potential Return- 35% - 40%
● Invest Duration- 12-14 Months
◉ Market Capitalization - $4.42 B
◉ Peer Companies
● Prestige Consumer Healthcare NYSE:PBH - $3.644 B
● Jazz Pharmaceuticals NASDAQ:JAZZ - $6.766 B
● Amphastar Pharmaceuticals NASDAQ:AMPH - $2.423 B
● Organon NYSE:OGN - $5.142 B
◉ Relative Strength
➖ The chart distinctly demonstrates that NASDAQ:CORT has significantly surpassed the US Smallcap 2000 index, attaining an impressive annual return of 30%, marking a remarkable accomplishment.
◉ Technical Aspects
● Monthly Chart
➖ The historical chart shows that the stock price is trending upward, marked by a sequence of higher highs and higher lows.
➖ Having recently moved out of the parallel channel, the price is set for additional gains.
● Daily Chart
➖ After an extended period of consolidation, the stock price has formed an Inverted Head & Shoulders pattern.
➖ Post-breakout, the stock has stabilized above the breakout point and is now striving for new highs.
➖ A surge in trading volume suggests that buyers are currently showing significant interest.
◉ Revenue & Profit Analysis
● Year-on-year
➖ In the fiscal year 2023, revenue experienced a significant increase of 20.4%, amounting to $482.4 million, compared to $401.9 million in fiscal year 2022.
➖ However, EBITDA faced a downturn, decreasing to $108.3 million in FY23 from $113.9 million in FY22.
➖ The EBITDA margin also saw a reduction, falling to 22.46% from 28.34% in FY22.
➖ Moreover, diluted earnings per share (EPS) rose by 8% year-over-year, climbing to $0.94 in FY23, up from $0.87 in FY22.
**While the growth in EBITDA might raise some concerns, it's crucial to acknowledge that the company is heavily investing in its research and development sector, and this investment has seen substantial increases over the years.
● Quarter-on-quarter
➖ In the most recent June quarter, the company reached an impressive achievement, with quarterly sales hitting a record high of $163.8 million. This represents a 12% increase from the $146.8 million reported in the March quarter and a substantial 39% growth compared to $117.7 million in the corresponding quarter of the previous year.
➖ Additionally, EBITDA rose from $29.6 million to $36.2 million during the latest quarter.
◉ Valuation
◉ PE Ratio
● PE vs Median PE
➖ Corcept Therapeutics sustained a median price-to-earnings ratio of 19.7x from December 2019 to 2023.
➖ Presently, with a price-to-earnings ratio of 35.3x, the stock seems to be relatively expensive.
● PE vs. Peers PE
➖ CORT's Price-To-Earnings Ratio stands at 35.3x, making it quite pricey when compared to the average of its peers, which is only 13.6x.
● PE vs. Industry PE
➖ CORT's valuation seems high, as it has a Price-To-Earnings Ratio of 35.3x, which is considerably above the US Pharmaceuticals industry average of 19x.
◉ PB Ratio
● PB vs. Peers PB
➖ The current price-to-book (P/B) ratio suggests that the stock is slightly undervalued, sitting at 7.4x compared to the peer average of 10.8x.
➖ However, it's important to note that a P/B ratio of 7.4x is typically seen as significantly overvalued.
● PB vs. Industry PB
➖ When we analyze the P/B ratio against the industry standard, CORT stands out as being notably overvalued, with its P/B ratio of 7.4x far exceeding the industry average of just 1.7x.
● PEG Ratio
➖ The stock currently seems to present a compelling investment opportunity, featuring a PEG ratio of 0.84.
◉ Cash Flow Analysis
➖ In FY23, operating cash flow increased to $127 million, compared to $120.3 million in FY22. However, it's essential to recognize that when examining the overall trend from FY19 to FY23, there has been a decline in cash flow from operations.
◉ Debt Analysis
➖ CORT operates without any debt, showcasing the robust financial health of the company.
◉ Top Shareholders
➖ Blackrock presently possesses a significant 15.8% ownership in this stock, while The Vanguard Group maintains approximately 9.1% stakes.
◉ Conclusion
Following a comprehensive examination of technical and fundamental metrics, our assessment indicates that Corcept Therapeutics possesses substantial growth potential within the US biotechnology sector. Notwithstanding elevated valuations, the company's increasing research and development expenditures demonstrate a strong commitment to its future prospects. Consequently, we consider Corcept Therapeutics a prudent investment choice at this juncture.
SPX macro analysis ⏰ Hello 👋 it's me your RAJ 🙂 professional trader ✨
This idea 💡
is completely my own analysis to explain situation _&_ market conditions of CBOE:SPX
How this chart valid for long term 📌 explained clearly based on technical #TA 📌 #DYOR
Let's go with market conditions 1st 👉
PPL 📌 thinking 🤔 big crash in S&P500 , based on economy and some other theories
I don't this things go , if this happens 😂 it will vanish not only stocks or companies even goverment also get vanish
Money 💰 >> PPL work / save in -> gold , bank & stocks
Money 💰 >> banks -> save in ->> gold , stocks & giving loan to company & PPL 📌
Money 💰 >> companies -> save in future growth 📈 give return to retailers and keep on increasing vlaue for future like NASDAQ:AAPL , NASDAQ:GOOG , NASDAQ:AMD etc ....
if stocks lose 📌 PPL lose 📌 if ppl lose 📌 goverment also lose 📌 biggest revaluation 😂
This is the major index ☝️ for many stocks , did you think 🤔 it will crash 🩸 that much harder 🙂
Use 🧠
👀 Let's go with my technical analysis ⏰ #TA ->> how I am expecting macro growth 💹
👀 There tend line 🙄 at previous High 2022 > to < 2023 which actually promised
trend 📉 line and even turned as resistance 📌 for 1.2yr
+
Finally it was broken and re-test also done 👍 turned as support 📌 💜💚 🚀
👀 According technical analysis 📌 my analysis get Invalid 📌 when month close below $3800.2
👀 There was oder block strong 🚀 support 📌 in 3 - month $4000-4200
👀 The previous order block at $4300 & $4600 easily broken 😂
These and some other theories making me push towards new high 💰
Expecting target's 🎯
🎯 :: $4880-$5018 ( easy target )
🎯 :: $5324-$5469 ( 💯 target )
🎯 :: $5885-$6484 ( high pressure resistance )
Support 📌 $3900-4200
This is my analysis on S&P500 on macro , i will post other patterns and chart of technical as per education under this post 📌
-----------------------------------------------------------------------------------------------------------------------------------------------------------
🪩 disclaimer :
▶️ TQ u for supporting 💚 follow idea 💡 get updates everytime ⏰ when I updated 📌
Note 👀
👉 keeping comments , reacting with emojis , pointing us is very easy to some people
They think 💬 what they see 📌 that was knowledge 📌
We need to learn market in many ways and should get adopted with experience, TECHNICAL ANALYSIS won't help understanding market structure and understanding bull 🐂 and bear 🐻 is more important
Economical conditions
Fundamentals
Technical
News
Sentiments
Checking macro to micro having good plan and build it is very important ☺️
Some Times market easily turn suddenly bear // bull 🤣 even we need to catch 🫴 those movements is also very important ☺️ 💛
I hope i cleared my view 🙂 if any points if I miss I will add in update 📌 post
Try to understand, try to learn - try to move with flexibility with market is important
Have good day 😊
TESLA - LONG TESLA is in downtrend since july 2023.
Currently the price has given the breakout from falling wedge with bullish div and now seems like the bulls are getting ready for some strong upside movement.
If the market continue to trend higher , the next optimum target could be 215-217
followed by 238-241.
BofA's Triumphant Return: Stock Surges to New Heights● Following a significant rejection around the 46.5 level, the stock price dropped nearly 50%.
● However, it found support near the 24.3 level and staged a comeback.
● After nearly three years, it has now broken through its previous major resistance and is currently trading at an all-time high.
● There are expectations that this upward momentum will continue, pushing the price even further.